1 March 2016 in Otolaryngology–Head and Neck Surgery
1 November 2018 in Ophthalmology
1 February 2022 in American Journal of Ophthalmology
27 July 2021 in International Ophthalmology
10 December 2023 in Ophthalmology
Sympathetic ophthalmia (SO) is a sight threatening granulomatous panuveitis caused by a sensitizing event. The use of primary enucleation or primary evisceration, versus primary repair, as a risk management strategy following OGI remains controversial. This systematic review was conducted to report the incidence of SO after primary repair compared to after primary enucleation or primary evisceration. This enabled the reporting of an estimated number needed to treat (NNT). Five journal databases were searched. This review was registered with PROSPERO: CRD42021262616. Searches were carried out on 29th June 2021 and updated 10th Dec 2022. Prospective or retrospective studies which reported outcomes (including sympathetic ophthalmia or lack of sympathetic ophthalmia) in a patient population who underwent either primary repair and primary enucleation, or primary evisceration, were included. A systematic review and meta-analysis were carried out in accordance with PRISMA guidelines. PROSPERO registration number CRD42021262616. Random effects modelling was used to estimate pooled SO rates and absolute risk reduction (ARR). Eight studies reporting SO as an outcome were included in total. The included studies contained 7500 patients and 7635 OGIs. In total 7620 OGIs met the criteria for inclusion in this analysis; 21 developed SO. When all included studies were pooled, the estimated SO rate was 0.12% (95% confidence interval (CI) 0.00% to 0.25%) after OGI. Out of 779 patients who underwent primary enucleation or primary evisceration no SO cases were reported, resulting in pooled SO estimate of 0.05% (95% CI 0.00% - 0.21%). For primary repair, the pooled estimate of SO rate was 0.15% (95% CI 0.00% to 0.33%). The ARR using a random effects model was -0.0010 (in favour of eye removal) (95% CI -0.0031 (in favour of eye removal) to 0.0011 (in favour of primary repair)). GRADE analysis highlighted a low certainty of evidence, as the included studies were observational and there was a risk of bias from missing data. Based on the available data, there is no evidence that primary enucleation or primary evisceration reduce the risk of secondary SO.
9 December 2020 in Journal of Vitreoretinal Diseases
This work aimed to analyze the 100 most-cited articles on antivascular endothelial growth factor (anti-VEGF) inhibitors. A literature search for anti-VEGF inhibitors using the Web of Science was completed using the bibliographic databases for peer-reviewed literature published in Ophthalmology, the New England Journal of Medicine, Journal of the American Medical Association, and Lancet. Primary outcomes were the most frequently cited articles and journals with the most citations as well as the specific drug and disease process studied. There were 42 696 cumulative citations among the top 100 articles. The articles were published between 2004 to 2016, with most articles published in 2006. Ophthalmology published the greatest number of articles among the top 100 at 48, whereas the New England Journal of Medicine has the most citations per publication at 1714. Ranibizumab was the medication researched in most articles at 56, followed by bevacizumab at 48, aflibercept at 10, and pegaptanib at 9. Forty-two articles investigated treatment of age-related macular degeneration, followed by 24 investigating diabetic macular edema, 10 for retinal vein occlusion, 8 for proliferative diabetic retinopathy, 2 for retinopathy of prematurity and polypoidal choroidal vasculopathy, and 1 for corneal neovascularization. As evidenced by the considerable number of citations accumulated over the past 20 years, anti-VEGF inhibitors have led to significant research in ophthalmology.